For instance, KRAS mutations which are widely detected in pancreatic cancers and colon cancers mediate multiple key glycolysis enzymes (such as HK-I/II, LDHA and GLUT1) thus leading glucose metabolism reprogramming (12, 13, 30, 32, 33). This evidence concerns the gene SLC2A1 and malignant colon neoplasm.